The only bit I'd correct is that it is not a certain 6-months for the further FDA review - it's "up to" 6 months, thus giving the FDA the potential to approve the drug before July next year (or whenever 6 months from resubmission is). Perhaps with it being such minor amendments to the application, the FDA may make a decision sooner rather than holdout for the full 6 months. Not saying it will happen like that - just saying the potential is available. I think BOT management are choosing the wiser course and giving dates that allow for the lengthiest option - better to surprise the market with good news of an earlier progression date than justify further delays IMO.
It would be nice if management provide a bit of an update following the FDA 30-day review meeting.
New Hartley Analyst report on Bot, page-89
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
-0.010(2.82%) |
Mkt cap ! $627.0M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 35.3¢ | 34.5¢ | $582.2K | 1.679M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 32454 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 210000 | 3 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |